Abstract:Genetic alterations (homozygous [biallelic] deletion and mutation) of BRCA1 BAP1 have been frequently observed and described as a critical event in the pathogenesis of malignant pleural mesothelioma (MPM) (Fig. 1A).1Testa J.R. Cheung M. Pei J. et al.Germline BAP1 mutations predispose to malignant mesothelioma.Nat Genet. 2011; 43: 1022-1025Crossref PubMed Scopus (761) Google Scholar As BAP1 is a tumor suppressor, its canonical roles are involved in the maintenance of genomic stability and the repair of DNA double-strand breaks (DSBs).2Yu H. Pak H. Hammond-Martel I. et al.Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.Proc Natl Acad Sci U S A. 2014; 111: 285-290Crossref PubMed Scopus (241) Google Scholar Thus, BAP1 loss-of-function is associated with defects in the repair of DSBs.2Yu H. Pak H. Hammond-Martel I. et al.Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.Proc Natl Acad Sci U S A. 2014; 111: 285-290Crossref PubMed Scopus (241) Google Scholar Given that poly(adenosine diphosphate–ribose) polymerase (PARP)–targeted therapies exhibit a synthetically lethal effect in tumors defective in homologous recombination repair of DSBs, susceptibility to PARP-targeted therapies has been revealed in cancer cells harboring BAP1 loss-of-function, including MPM.2Yu H. Pak H. Hammond-Martel I. et al.Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.Proc Natl Acad Sci U S A. 2014; 111: 285-290Crossref PubMed Scopus (241) Google Scholar,3Parrotta R. Okonska A. Ronner M. et al.A novel BRCA1-associated Protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair.J Thorac Oncol. 2017; 12: 1309-1319Abstract Full Text Full Text PDF PubMed Scopus (39) Google Scholar In a recent study, Rathkey et al.4Rathkey D. Khanal M. Murai J. et al.Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-Schlafen 11 and low-O6-methylguanine-DNA methyltransferase expression [e-pub ahead of print]. J Thorac Oncol.https://doi.org/10.1016/j.jtho.2020.01.012Google Scholar investigated the association of genetic alterations of BAP1 with the sensitivity to PARP inhibition in a panel of patient-derived primary MPM cells harboring various types of BAP1 alterations. Surprisingly, in contrast with previous studies,2Yu H. Pak H. Hammond-Martel I. et al.Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.Proc Natl Acad Sci U S A. 2014; 111: 285-290Crossref PubMed Scopus (241) Google Scholar,3Parrotta R. Okonska A. Ronner M. et al.A novel BRCA1-associated Protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair.J Thorac Oncol. 2017; 12: 1309-1319Abstract Full Text Full Text PDF PubMed Scopus (39) Google Scholar this work revealed that the sensitivity of MPM cells to PARP inhibitors is independent of BAP1 mutational status. To carry out cross-validation, we integrated the high-throughput drug screen data from the publicly available database, Genomics of Drug Sensitivity in Cancer (https://www.cancerrxgene.org/), which assays hundreds of drug compounds containing several selective PARP inhibitors on approximately 1000 human cancer cell lines including MPM (n = 20) and the genetic landscape of the respective cell lines on the basis of the Cancer Cell Line Encyclopedia project. We extracted the drug sensitivity data of MPM cell lines and observed a fraction of these cell lines, including BAP1-altered (H2804, IST-MES1, and H2795) and wild-type (H2803 and MSTO-211H) that are particularly sensitive to PARP inhibitors. This is determined by the low IC50 z-score (≤ -1) to various PARP1 inhibitors (talazoparib, olaparib, veliparib, and rucaparib) compared with that of other molecule-targeted agents (Fig. 1B). Notably, some BAP1-mutant MPM cells (H2452, H2731, and H2722) are even more highly resistant to multiple PARP inhibitors. These data suggest that BAP1-mutant MPM cells display highly heterogeneous susceptibility to PARP inhibitors, which provides an additional layer of evidence supporting the work of Rathkey et al.4Rathkey D. Khanal M. Murai J. et al.Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-Schlafen 11 and low-O6-methylguanine-DNA methyltransferase expression [e-pub ahead of print]. J Thorac Oncol.https://doi.org/10.1016/j.jtho.2020.01.012Google Scholar This high heterogeneity might be explained by the following: (1) the presence of co-occurring mutations with genetic alterations of BAP1 in MPM (Fig. 2), which might lead to the varying responses to PARP inhibitors given that tumorigenesis is a complex process involving a gradual accumulation of genetic alterations; (2) some specific BAP1 splice isoform can affect the response to PARP inhibition,3Parrotta R. Okonska A. Ronner M. et al.A novel BRCA1-associated Protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair.J Thorac Oncol. 2017; 12: 1309-1319Abstract Full Text Full Text PDF PubMed Scopus (39) Google Scholar indicating that further stratifications might be warranted to guide PARP-targeted therapy among patients with BAP1-mutant MPM; (3) BAP1 has multifaceted functions beyond its involvement in the genomic stability and repair of DSBs,5Zhang Y. Shi J. Liu X. et al.BAP1 links metabolic regulation of ferroptosis to tumour suppression.Nat Cell Biol. 2018; 20: 1181-1192Crossref PubMed Scopus (366) Google Scholar implying that subtype-specific alterations might result in different biological aberrations; and (4) the cell lineage (MPM versus non-MPM) might play a role in the response to PARP inhibition. In summary, BAP1 mutational status in MPM does not seem to affect the sensitivity to PARP-targeted therapy. Further studies investigating the association of BAP1-mutational status with homologous recombination deficiency and sensitivity to PARP inhibition are required. This work was supported by PhD fellowship from the China Scholarship Council (to Dr. Yang and Dr. Gao) and a grant from Swiss Cancer League/Swiss Cancer Research (#KFS-4851-08-2019; to Dr. Peng). Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase ExpressionJournal of Thoracic OncologyVol. 15Issue 5PreviewBRCA1-associated protein-1 (BAP1), a nuclear deubiquitinase thought to be involved in DNA double-strand break repair, is frequently mutated in mesothelioma. Because poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPIs) induce synthetic lethality in BRCA1/2 mutant cancers, we evaluated whether BAP1 inactivating mutations confer sensitivity to PARPIs in mesothelioma and if combination therapy with temozolomide (TMZ) would be beneficial. Full-Text PDF Open Archive

Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma

Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma

The Association of BAP1 Loss-of-Function with the Defect in Homologous Recombination Repair and Sensitivity to PARP-Targeted Therapy

Safety and Efficacy of EZH2 and BRD4 Dual Targeting in EZH2Y641mut Germinal Centre-Derived Lymphoma

Loss of RNF2 delays tumour development in BAP1-deficient mesothelioma

Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy

EZH2 Expression is Increased in BAP1-mutant Renal Clear Cell Carcinoma and is Related to Poor Prognosis

ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma

EZH2 inhibition sensitizes MYC-high medulloblastoma cancers to PARP inhibition by regulating NUPR1-mediated DNA repair

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas

Efficacy of Protac-Based EZH2 Degrader MS1943 in Lymphoid Malignancies: A Comprehensive Study on the Combined Effects of MS1943 and Ibrutinib

Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas

Abstract 4589: Synergistic effects of EZH1/2 dual inhibition and cisplatin on lung cancer cell lines with loss of SMARCA4 and SMARCA2

Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects

BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma

EZH2-mediated development of therapeutic resistance in cancer

Combined inhibition of EZH2 and CDK4/6 perturbs endoplasmic reticulum-mitochondrial homeostasis and increases antitumor activity against glioblastoma

Maximizing Anticancer Response with MPS1 and CENPE Inhibition Alongside Apoptosis Induction

BAP1 loss augments sensitivity to BET inhibitors in cancer cells

Inhibition of EZH2 and EGFR produces a synergistic effect on cell apoptosis by increasing autophagy in gastric cancer cells.

Identification of Coexistence of BRAF V600E Mutation and EZH2 Gain Specifically in Melanoma As a Promising Target for Combination Therapy